Brain-computer interfaces are no longer a distant science-fiction concept
Brain-computer interfaces are no longer a distant science-fiction concept. Several companies are now conducting human clinical trials, with real patients using implanted devices to restore lost capabilities or explore new forms of human-computer interaction. The field is moving faster than most people realize.
This article examines the four leading companies in invasive brain-computer interface research and development — Neuralink, Precision Neuroscience, Synchron, and Blackrock Neurotech — their different technical approaches, their progress in human trials, and what the competitive landscape means for the future of medicine and human augmentation.
Neuralink: The most visible player
Elon Musk's Neuralink has attracted the most public attention, in part because of its founder's profile and in part because of its stated ambitions, which extend well beyond medical applications to include cognitive enhancement and eventual symbiosis between human intelligence and AI.
Neuralink's device, called the N1 implant, contains over a thousand electrodes and is surgically inserted by a custom robotic system. The company received FDA approval for a human trial in 2023 and implanted its first human patient in early 2024. Early results showed that the patient could control a computer cursor with thought alone — a result that has been reproduced by other BCI systems but represents a proof of concept for Neuralink's approach.
The company's longer-term goal is a device that can be implanted and removed as easily as a contact lens, enabling elective adoption by healthy individuals seeking cognitive augmentation rather than only patients with medical need.
Precision Neuroscience: The thin-film alternative
Precision Neuroscience, co-founded by a former Neuralink executive, is pursuing a different approach to implantation. Rather than inserting probe-like electrodes into brain tissue, Precision's "Layer 7 Cortical Interface" sits on the surface of the brain — a thin, flexible film containing hundreds of electrodes that conforms to the brain's natural curves.
The surface placement is less invasive than depth electrodes, which Precision argues will make it easier to achieve widespread adoption for medical applications. The company has completed several human procedures and is gathering data on the quality of neural signals achievable from the cortical surface.
Synchron: The endovascular approach
Synchron takes perhaps the most distinctive approach of the four companies. Rather than opening the skull to place electrodes on or in brain tissue, Synchron's "Stentrode" device is delivered through blood vessels — inserted via a catheter in the jugular vein and navigated to a position in the motor cortex, where it expands to press against the vessel wall and record neural signals.
The endovascular approach means no brain surgery is required, which significantly reduces the risks associated with implantation and recovery. Synchron received FDA approval for its COMMAND trial in 2021 and has implanted patients in both the United States and Australia. Several patients have used the device to control computers and communicate using their thoughts.
The trade-off is signal quality: electrodes inside blood vessels are necessarily further from the neurons of interest than depth electrodes or surface arrays, which means the signals recorded tend to be lower resolution. For many communication and control applications, however, the current signal quality has proven adequate.
Blackrock Neurotech: The established incumbent
Blackrock Neurotech has the longest track record in human BCI trials of any company in this space. The company's "Utah Array" — a grid of 100 electrodes on a 4mm x 4mm silicon substrate — has been used in more human patients than any other BCI device and has been the workhorse of academic BCI research for decades.
Blackrock has used this foundation to develop commercial BCI systems and has conducted trials with patients controlling robotic arms, communicating through speech synthesis, and regaining sensation in paralyzed limbs through electrical stimulation.
The company's challenge is that its core technology is mature and well-understood, which gives it credibility but also means it faces competition from newer approaches that may offer better performance or lower procedural risk.
The competitive dynamics
The four companies represent meaningfully different bets on the right trade-offs for BCI development:
| Company | Approach | Key advantage | Key challenge |
|---|---|---|---|
| Neuralink | High-density depth electrodes, robotic surgery | Highest resolution signals | Most invasive; regulatory scrutiny |
| Precision Neuroscience | Flexible surface array | Less invasive than depth; easy removal | Lower signal quality than depth |
| Synchron | Endovascular | No brain surgery required | Lower signal resolution |
| Blackrock | Utah Array (established platform) | Proven track record; academic credibility | Mature technology; competition from newer approaches |
What comes next
The near-term applications of BCI technology are clearly medical: restoring communication and motor control to people with paralysis, amyotrophic lateral sclerosis, and other conditions that sever the connection between intent and action. These applications have clear value and are the basis for the regulatory approvals that all four companies are pursuing.
Longer term, the technology raises profound questions about human identity, privacy, and equity. If BCIs become capable of enhancing cognition — improving memory, attention, or processing speed — who will have access? How will neural data be protected? What happens when the boundary between biological and digital intelligence becomes permeable?
These questions will not be resolved anytime soon. But the pace of technical progress in the field means they will need to be addressed sooner than many people expect.
Looking to optimize community management?
We have prepared materials on BASE best practices and success stories.
Streamline event operations with AI | TIMEWELL Base
Struggling to manage large-scale events?
TIMEWELL Base is an AI-powered event management platform.
Proven Track Record
- Adventure World: Managed Dream Day with 4,272 participants
- TechGALA 2026: Centrally managed 110 side events
Key Features
| Feature | Impact |
|---|---|
| AI Page Generation | Event page ready in 30 seconds |
| Low-cost payments | 4.8% fee — industry's lowest |
| Community features | 65% of attendees continue networking after events |
Ready to make your events more efficient? Let's talk.